The current study shows that SGLT2 inhibitor treatment may induce osmotic vacuolization of proximal tubular epithelial cells and AKI for T2DM patients unable to manage a stable weight range. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.